Software as a Service (SaaS) allows researchers to concentrate on their work without the need for complex IT infrastructure, thereby expediting research progress and streamlining processes. Continual refinement of SaaS programs is essential to tackle evolving challenges and technological limitations, providing researchers with gradual enhancements that aid in their pursuit of innovative discoveries, one step at a time

Small Molecule DRUG candidate : Sm-ARS
Sm-ARS utilizes AI to predict the three-dimensional structure of protein-compound binding, calculate binding affinities, and select optimal structures. Through molecular dynamics simulations, thereby yielding more accurate results.

Neoantigen prediction : NEO-ARS®
AI neoantigen prediction platform integrates tumor heterogeneity and immunological knowledge, utilizing tailored algorithms with consideration for experimental validation, capable of: 1) developing personalized cancer vaccines, and 2) contributing to the development of universal (off-the-shelf) cancer vaccines.

Antibody DRUG candidate : Ab-ARS®
Ab-ARS®'s CDR generator provides a solution that addresses accuracy, efficiency, and speed issues through CDR prediction generation based on complex antibody structures and the diversity of CDRs, while considering therapeutic efficacy.